TY - JOUR
T1 - Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer
AU - Anderson, K. S.
AU - Wong, J.
AU - D'Souza, G.
AU - Riemer, A. B.
AU - Lorch, J.
AU - Haddad, R.
AU - Pai, S. I.
AU - Longtine, J.
AU - McClean, M.
AU - Labaer, J.
AU - Kelsey, K. T.
AU - Posner, M.
N1 - Funding Information:
This study was supported by a research grant from the Early Detection Research Network 5U01CA117374 (KSA and JL), the Friends of the Dana-Farber Head and Neck Cancer Research Fund (KSA and MP), CA078609 (KTK) and CA100679 (KTK). We thank
PY - 2011/6/7
Y1 - 2011/6/7
N2 - Background:Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.Methods:Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N40), partners of patients with HPV16 OPC (N11), and healthy controls (N50).Results:Oropharyngeal carcinomas patients with known virus-like capsid particle Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P0.02) and partners of OPC patients (P0.01).Conclusion:Patients with HPV16 OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.
AB - Background:Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.Methods:Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N40), partners of patients with HPV16 OPC (N11), and healthy controls (N50).Results:Oropharyngeal carcinomas patients with known virus-like capsid particle Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P0.02) and partners of OPC patients (P0.01).Conclusion:Patients with HPV16 OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.
KW - HPV
KW - Luminex
KW - autoantibodies
KW - biomarker
KW - head and neck cancer
UR - http://www.scopus.com/inward/record.url?scp=79958087380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958087380&partnerID=8YFLogxK
U2 - 10.1038/bjc.2011.171
DO - 10.1038/bjc.2011.171
M3 - Article
C2 - 21654689
AN - SCOPUS:79958087380
SN - 0007-0920
VL - 104
SP - 1896
EP - 1905
JO - British journal of cancer
JF - British journal of cancer
IS - 12
ER -